
    
      OUTLINE: This is a dose-escalation study.

      Patients receive azacitidine intravenously (IV) over 10-40 minutes or subcutaneously (SC) on
      days 1 and 15, days 1-2 and 15-16, days 1-3 and 15-17, or days 1-4 and 15-18. Patients also
      receive erlotinib hydrochloride orally (PO) daily on days 1-21. Courses repeat every 28 days
      in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed for 28 days and then every 3
      months for 5 years.
    
  